Exact Sciences's 15min chart triggers Bollinger Bands narrowing, KDJ death cross.

Based on the 15-minute chart of Exact Sciences, a narrowing of Bollinger Bands has been observed, accompanied by a KDJ Death Cross at 09/08/2025 13:30. This indicates a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, with potential further decreases in stock price.

The liquid biopsy market in cancer diagnostics is poised for robust growth, driven by rising cancer incidence and the demand for minimally invasive, precision medicine approaches. According to DelveInsight's report, the global liquid biopsy market is projected to reach USD 19.24 billion by 2032, growing at a CAGR of 16.64% [1].

Market Overview
Liquid biopsy, a revolutionary approach in cancer diagnostics, involves analyzing bodily fluids such as blood, urine, and saliva to detect cancer-related genetic mutations, circulating tumor cells (CTCs), and cell-free DNA (cfDNA). Unlike traditional tissue biopsies, liquid biopsy offers a non-invasive, real-time view of the tumor's genetic landscape, enabling oncologists to monitor disease progression, assess treatment response, and identify potential therapeutic targets with greater precision.

Market Dynamics
Several factors are driving the growth of the liquid biopsy market. The rising global cancer burden is a significant driver, with increasing prevalence of cancers such as lung, breast, colorectal, and liver. Minimally invasive testing, precision medicine adoption, technological advancements, regulatory support, and clinical applications are also key drivers. However, procedural limitations, lack of standardization, high cost, and limited awareness pose challenges to market growth.

Key Players
Notable companies operating in the liquid biopsy market include Myriad Genetics Inc., Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., and several others [1].

Recent Developments
In April 2025, Labcorp announced the expansion of its precision oncology portfolio with two new offerings: Labcorp Plasma Detect and PGDx elio plasma focus Dx. Tempus AI, Inc. launched its FDA-approved NGS-based in vitro diagnostic test, xT CDx, in January 2025. Oxford Cancer Analytics raised $11 million in a Series A funding round to develop and commercialize novel liquid biopsy blood tests for lung cancer early detection. PrognomiQ and Aditxt, Inc. have also made significant strides in the market, further underscoring the potential of liquid biopsy in improving patient outcomes [1].

Market Outlook
The liquid biopsy market is expected to expand significantly from 2025 to 2032, driven by the factors mentioned above. The market is segmented by type (instruments, reagents & kits, services), sample type (blood, urine, saliva), biomarker (CTCs, ctDNA, cfDNA), cancer type (lung, breast, colon, others), technique (PCR, NGS), end-user (hospitals, diagnostic centers), and geography (North America, Europe, Asia-Pacific, Rest of the World) [1].

References
[1] https://www.barchart.com/story/news/34577083/liquid-biopsy-in-cancer-diagnostics-market-to-witness-robust-17-cagr-expansion-by-2032-delveinsight